Mereo BioPharma Group plc
(NASDAQ: MREO)
|
5:00 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $3.59 | Change: +0.14 | %Change: +4.06% | Volume: 298,573 |
Open: | $ 3.40 | Volume: | 298,573 | |
---|---|---|---|---|
High: | $ 3.61 | Yield(%) | 0.00 | |
Low: | $ 3.37 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 483.93M | |
EPS ($) | -0.06 | Shares Out: | 140.27M |
% Price Change (last 4 weeks): | 3.60 |
---|---|
% Price Change (last 13 weeks): | 2.07 |
% Price Change (last 26 weeks): | 50.00 |
% Price Change (last 52 weeks): | 167.44 |
% Price Change (year to date): | 49.35 |
Return on Equity (%): | -47.34 |
---|---|
Return on Assets (%): | -34.31 |
Return on Invested Capital (%): | -135.65 |
Gross Profit Margin (%): | 63.65 |
---|---|
Net Profit Margin (%): | -294.66 |
Operating Profit Margin (%): | -284.16 |
50-day Moving Average: | $3.33 |
---|---|
200-day Moving Average: | $2.77 |
Avg. Daily Vol. (last 50 days): | 1,144,898 |
Avg. Daily Vol. (last 200 days): | 1,341,357 |
52-wk high: | $4.50 |
52-wk low: | $1.07 |
Bid: | $3.45 |
Ask: | $3.61 |
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
|
Mereo BioPharma Group plc
1 Cavendish Place 4th Floor London GL W1G 0QF Phone: 44.333.023.7300 Fax: n/a http://www.mereobiopharma.com |
Earnings (1year) ($): | -0.25 |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 0.36 |
Cash Flow ($): | -0.20 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | 30.35 |
Price/Book (x): | 6.40 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 6.72 |
---|---|
Current Ratio (x): | 6.72 |
LT Debt/Equity (x): | 10.49 |
Total Debt/Equity (x): | 11.78 |